[Clinical results of a double blind study with the new antirheumatic agent acemetacin (author's transl)].
In a controlled double blind study the therapeutic efficacy of equimolar doses of [1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-acetoxy] acetic acid (acemetacin, TV 1322, Rantudil¿) and indometacin was compared in 32 male and 32 female patients suffering from arthrosis deformans of the large joints or vertebral syndromes. No significant differences were observed between the two substances with regard to the therapeutic efficacy and in the clinical laboratory data. Side effects occurred less frequently under acemetacin than under indometacin; in particular no gastro-intestinal complaints were observed under acemetacin.